Summary: The FDA has approved Elevidys, the first gene therapy for treating pediatric patients aged 4-5 with Duchenne muscular dystrophy (DMD) and a confirmed DMD gene mutation. This approval addresses an urgent medical need for a devastating condition with limited treatment options. Elevidys aims to improve outcomes and quality of life for affected patients.